Sign In
Buy TWST
$91.55
+0.220 (+0.241%)
At Close: Jul 31, 2026
Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates
09:25am, Monday, 02'nd Feb 2026
Twist Bioscience (TWST) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.53 per share a year ago.
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
07:15am, Monday, 02'nd Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the
The Genesis Mission Has a 270-Day Timeline – And You’re Already Late
12:00am, Tuesday, 27'th Jan 2026
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know
11:00am, Monday, 26'th Jan 2026
Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Twist Bioscience (NASDAQ:TWST) CFO Sells $120,000.00 in Stock
05:40am, Sunday, 18'th Jan 2026
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) CFO Adam Laponis sold 3,000 shares of the business's stock in a transaction dated Tuesday, January 13th. The shares were sold at an averag
Twist Bioscience Corporation (NASDAQ:TWST) Given Average Rating of “Moderate Buy” by Analysts
02:02am, Sunday, 18'th Jan 2026
Shares of Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the stock, Marketbeat.com report
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:56pm, Monday, 12'th Jan 2026
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue
08:00am, Monday, 12'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quar
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure
12:23pm, Monday, 05'th Jan 2026
Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab
06:26am, Wednesday, 31'st Dec 2025
Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while
TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock
12:51pm, Monday, 29'th Dec 2025
Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin
The Genesis Mission Has a 270-Day Timeline – And You’re Already Late
12:00am, Saturday, 20'th Dec 2025
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade
12:00am, Saturday, 20'th Dec 2025
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference
08:00am, Thursday, 18'th Dec 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder
Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights
01:15pm, Friday, 12'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciar
